Biomaterials - Market Insights, Competitive Landscape, and Market Forecast - 2034

Published Date : 2026
Pages : 150
Region : Global,
Delivery Timeline : 24 Hours

Biomaterials Market Summary

  • The Biomaterials market size is estimated at USD 52 billion in 2025 and is projected to reach USD 162 billion by 2034. Growth is anchored in rising demand for implantable medical devices, an aging population with a high burden of chronic disease, and rapid advances in regenerative medicine, bioresorbable materials, and additive manufacturing.
  • The global Biomaterials market is growing at a CAGR of 13.5% during the forecast period from 2026 to 2034.
  • By type of material, the metallic biomaterials segment dominated the Biomaterials market with a 37% share in 2025.
  • By application, the cardiovascular segment dominated the Biomaterials market with a share of 26% in 2025.
  • By end-user, the hospitals and clinics segment dominated the Biomaterials market with a share of 50% in 2025.
  • North America dominated the global Biomaterials market revenue with a share of 35% in 2025, representing the highest regional market share globally.

Biomaterials are natural or synthetic materials engineered to interact with biological systems for medical purposes, used to repair, replace, support, or augment tissues, organs, and bodily functions. The category spans metallic biomaterials such as titanium, stainless steel, and cobalt-chromium alloys used in orthopedic, cardiovascular, and dental implants; polymeric biomaterials including high-performance and bioresorbable polymers such as polyether ether ketone and polylactic acid; ceramic biomaterials such as hydroxyapatite, alumina, and zirconia; and natural biomaterials such as collagen, hyaluronic acid, and other biologically derived materials. These materials are supplied by medical device companies including Zimmer Biomet, Stryker, Medtronic, and Johnson & Johnson, and by specialty material manufacturers including Evonik through its RESOMER bioresorbable and biomaterials portfolio, Victrex and Invibio through PEEK-OPTIMA polymers, BASF, Corbion, and natural biomaterial suppliers. Biomaterials are used across cardiovascular, orthopedic, dental, ophthalmology, wound healing, tissue engineering, plastic surgery, and neurology applications, in hospitals, clinics, and other settings. Over the past decade, the field has advanced with bioresorbable and bioactive materials, additive manufacturing of patient-specific implants, and regenerative medicine and tissue engineering. Driven by rising demand for medical implants, an aging population, and rapid technological innovation, biomaterials constitute one of the largest and fastest-growing segments of the medical materials and device industry.

Biomaterials Market Key Growth Drivers

  • Rising demand for implantable medical devices, including orthopedic, cardiovascular, and dental implants, is expanding demand for biomaterials.
  • The aging global population and rising burden of chronic diseases, including cardiovascular and musculoskeletal conditions, are increasing the need for implants and biomaterials.
  • Rapid growth in regenerative medicine and tissue engineering is expanding demand for advanced and natural biomaterials and scaffolds.
  • Technological advances, including bioresorbable and bioactive materials, additive manufacturing, and surface engineering, are expanding biomaterial applications and performance.
  • The rising volume of orthopedic, cardiovascular, and dental procedures is increasing demand for implant biomaterials.
  • Growing research and development investment and collaboration between material and device companies are accelerating biomaterial innovation.
  • The convergence of rising implant demand, population aging, and material innovation is expected to sustain strong growth in the global Biomaterials market through 2034.

Key Companies in Biomaterials Market

The competitive landscape is led by the following active developers and manufacturers of biomaterials and biomaterial-based devices:

  • Zimmer Biomet Holdings, Inc.
  • Stryker Corporation
  • Medtronic plc
  • Johnson & Johnson
  • Evonik Industries AG
  • BASF SE
  • Corbion N.V.
  • Victrex plc
  • Institut Straumann AG
  • Collagen Matrix, Inc., and others

For illustrative purposes, only the top 10 companies are listed in the Table of Contents. The report may include analysis and references to additional companies relevant to the market assessment.

Biomaterials Market Size

The following snapshot summarizes the principal report metrics for the Biomaterials market.

Report Metrics

Details

2025 Market Size

USD 52 billion

2034 Projected Market Size

USD 162 billion

Growth Rate (2026-2034)

13.5% CAGR

Largest Market

North America

Fastest Growing Market

Asia-Pacific

Market Structure

Fragmented

All market values are expressed in USD and represent DelveInsight estimates synthesized from primary and secondary research.

Factors Contributing to the Growth of the Biomaterials Market

Biomaterials Market Drivers

  • Rising Demand for Implantable Medical Devices: The rising demand for implantable medical devices is the foundational driver of the biomaterials market. Biomaterials are the essential building blocks of orthopedic implants such as joint replacements and spinal devices, cardiovascular devices such as stents, heart valves, and vascular grafts, dental implants, and many other medical devices. The growing volume of implant procedures worldwide, driven by aging populations, rising chronic disease, and expanding access to surgical care, directly increases demand for the metallic, polymeric, ceramic, and natural materials used to manufacture these devices. Device manufacturers increasingly adopt advanced biomaterials, including high-performance polymers such as polyether ether ketone and bioresorbable materials, to improve outcomes. As the demand for implantable medical devices continues to rise across orthopedics, cardiovascular, dental, and other fields, demand for biomaterials continues to grow, reinforcing sustained market growth throughout the forecast period.
  • Aging Population and Rising Chronic Disease Burden: The aging of the global population and the rising burden of chronic disease are powerful drivers of biomaterials demand. Older adults carry a substantially higher prevalence of musculoskeletal conditions requiring joint replacement and spinal surgery, cardiovascular disease requiring stents, valves, and grafts, and tooth loss requiring dental implants, and the number of people aged 60 and older is rising rapidly worldwide. This demographic shift expands the population requiring implants and biomaterial-based devices. The rising global burden of cardiovascular disease, osteoarthritis, osteoporosis, and other chronic conditions further increases demand for implants and reconstructive materials. As populations age and the burden of chronic and degenerative disease grows, demographic trends are expected to be a significant driver of biomaterials demand across the forecast period.
  • Growth of Regenerative Medicine and Tissue Engineering: The rapid growth of regenerative medicine and tissue engineering is a defining driver of the biomaterials market. Biomaterials, including natural materials such as collagen and hyaluronic acid and advanced synthetic scaffolds, are central to tissue engineering, wound healing, and regenerative approaches that aim to repair or regenerate tissues and organs. The development of scaffolds, hydrogels, and bioactive and bioresorbable materials supports applications in wound care, bone and cartilage repair, and emerging cell and tissue therapies, and additive manufacturing enables patient-specific scaffolds and constructs. Growing investment and research in regenerative medicine expand the demand for advanced biomaterials. As regenerative medicine and tissue engineering continue to advance and move toward clinical application, they are expected to be a significant driver of biomaterials market growth across the forecast period, particularly for natural and advanced synthetic materials.
  • Technological Advancement in Materials and Manufacturing: Continuous technological innovation in materials and manufacturing is expanding biomaterial applications and performance and driving market growth. Bioresorbable polymers such as those in Evonik's RESOMER portfolio enable implants and devices that are absorbed by the body over time, eliminating the need for removal, and high-performance polymers such as polyether ether ketone, exemplified by Victrex and Invibio's PEEK-OPTIMA, provide strong, radiolucent, and biocompatible alternatives to metal. Additive manufacturing, or three-dimensional printing, of titanium, polymer, and ceramic implants enables patient-specific, porous, and complex geometries that improve integration and outcomes, and surface engineering and bioactive coatings improve osseointegration and biocompatibility. Bioactive ceramics and composites expand bone repair applications. These innovations expand the range of applications, improve clinical outcomes, and differentiate products. As biomaterials and manufacturing technologies continue to advance, technological innovation is expected to be a significant driver of market growth across the forecast period.
  • Rising Volume of Orthopedic, Cardiovascular, and Dental Procedures: The rising volume of orthopedic, cardiovascular, and dental procedures is a substantial driver of biomaterials demand. The growing number of joint replacements, spinal surgeries, trauma fixations, cardiovascular interventions such as stenting and valve replacement, and dental implant procedures directly increases consumption of implant biomaterials. Aging populations, rising disease burden, expanding access to surgical and dental care, and improving affordability in emerging markets drive procedure growth. Each procedure consumes biomaterial-based implants and devices, generating sustained and growing demand. The growth of minimally invasive and advanced procedures further expands the use of specialized biomaterials. As procedure volumes continue to rise across orthopedics, cardiovascular medicine, and dentistry, this growth is expected to be an important driver of biomaterials demand across the forecast period.
  • Growing Research Investment and Industry Collaboration: Growing research and development investment and collaboration between material and device companies are accelerating biomaterial innovation and market growth. Specialty material manufacturers such as Evonik, BASF, Corbion, and Victrex collaborate closely with medical device companies to develop and supply advanced biomaterials tailored to device applications, and significant investment flows into bioresorbable materials, high-performance polymers, bioactive ceramics, and natural biomaterials. Academic, government, and industry research in biomaterials, regenerative medicine, and additive manufacturing continues to expand the pipeline of new materials and applications. Partnerships, licensing, and acquisitions accelerate the translation of materials into devices. This investment and collaboration expand the availability and performance of biomaterials. As research investment and industry collaboration continue to drive biomaterial innovation, they are expected to be an important driver of market growth across the forecast period.

Biomaterials Market Restraints

Despite strong momentum, the Biomaterials market faces material constraints. Stringent and evolving regulatory requirements for implantable materials and devices, including Food and Drug Administration pathways and the European Medical Device Regulation, add substantial cost, complexity, and time to development and market entry, and biomaterials face rigorous biocompatibility and long-term safety testing. Concerns regarding biocompatibility, long-term performance, wear, degradation, and the risk of adverse reactions, inflammation, or implant failure constrain adoption and require extensive validation. The high cost of advanced biomaterials and of their development, testing, and manufacturing limits adoption, particularly in cost-sensitive and emerging markets. The risk of implant-associated infection and complications adds clinical considerations. Natural and biologically derived biomaterials raise sourcing, variability, immunogenicity, and ethical considerations. Intellectual property, supply chain, and raw material constraints can affect availability and cost. Reimbursement pressures and cost-containment in healthcare systems constrain device pricing and, indirectly, biomaterial adoption. Finally, the long development and approval timelines for new materials and the conservative adoption of novel materials in high-risk implants can slow market entry across parts of the forecast period.

Biomaterials Market Segment Analysis

The Biomaterials Market is segmented by type of material (metallic biomaterials, polymeric biomaterials, ceramic biomaterials, natural biomaterials), application (cardiovascular, orthopedic, dental, ophthalmology, wound healing, tissue engineering, plastic surgery, neurology, others), end-user (hospitals and clinics, ambulatory surgical centers, academic and research institutes, others), and geography (North America, Europe, Asia-Pacific, Rest of World).

By Type of Material

Dominant Subsegment: Metallic Biomaterials.

The metallic biomaterials segment accounted for 37% of the Biomaterials market in 2025. Metallic biomaterials dominate because titanium and titanium alloys, stainless steel, and cobalt-chromium alloys are the established materials for load-bearing and structural implants, including orthopedic joint replacements, spinal and trauma devices, dental implants, and cardiovascular devices such as stents. Their strength, durability, fatigue resistance, and biocompatibility make them the materials of choice for the large and high-value orthopedic and cardiovascular implant markets, driving the largest share of biomaterials revenue. Polymeric biomaterials represent a large and rapidly growing segment, including high-performance polymers such as polyether ether ketone from Victrex and Invibio and bioresorbable polymers from Evonik, used in spinal, trauma, and soft-tissue applications and increasingly replacing metal in some uses. Ceramic biomaterials, including hydroxyapatite, alumina, and zirconia, are important in orthopedic, dental, and bone repair applications, and natural biomaterials such as collagen and hyaluronic acid are central to wound healing, tissue engineering, and regenerative medicine and are growing rapidly. Nonetheless, the strength, established use, and dominance of metals in high-value structural implants secure the leadership of the metallic biomaterials segment across the forecast period, with polymers and natural materials growing strongly.

By Application

Dominant Subsegment: Cardiovascular.

The cardiovascular segment accounted for 26% of the Biomaterials market in 2025. The cardiovascular application dominates because biomaterials are essential to a large and high-volume range of cardiovascular devices, including coronary and peripheral stents, heart valves, vascular grafts, pacemaker and device components, and catheters, and the high global burden of cardiovascular disease drives extensive use. Metallic, polymeric, and natural biomaterials are used across these devices, and the large volume of cardiovascular interventions worldwide generates substantial demand. The orthopedic application represents a very large and closely competing segment, driven by joint replacements, spinal devices, and trauma fixation that consume large volumes of metallic, polymeric, and ceramic biomaterials, and is a leading application in many markets. Dental applications are large and growing, driven by dental implants and bone grafting materials, and ophthalmology, wound healing, tissue engineering, plastic surgery, and neurology add substantial demand. Nonetheless, the breadth, volume, and high burden of disease in cardiovascular applications secure the leadership of this segment across the forecast period, with orthopedic applications closely following.

By End-User

Dominant Subsegment: Hospitals and Clinics.

The hospitals and clinics segment accounted for 50% of the Biomaterials market in 2025. Hospitals and clinics dominate because they are the primary settings where biomaterial-based implants and devices are used, through orthopedic, cardiovascular, dental, and reconstructive surgical procedures. The concentration of implant surgery, cardiovascular intervention, and complex procedures in hospitals drives the largest share of biomaterial consumption, as hospitals perform the majority of joint replacements, spinal surgeries, cardiovascular device implantations, and other biomaterial-intensive procedures. Ambulatory surgical centers represent a large and growing end user, performing increasing volumes of orthopedic, dental, and other procedures as surgery shifts to outpatient settings, benefiting from efficiency and cost advantages. Academic and research institutes are important end users for biomaterials research, tissue engineering, and development, and other settings, including dental and specialty clinics, add further demand. Nonetheless, the concentration of implant and device procedures in hospitals and clinics secures the leadership of this segment across the forecast period, with ambulatory surgical centers growing as procedures shift to outpatient care.

Biomaterials Market Region Analysis

North America accounted for 35% of the global Biomaterials market revenue in 2025, representing the highest regional market share globally. The region's dominance reflects advanced healthcare infrastructure, high volumes of orthopedic, cardiovascular, and dental procedures, rapid adoption of advanced biomaterials, and the presence of leading device and material manufacturers. The United States leads on the strength of a large implant and device market, high procedure volumes, early adoption of advanced materials such as high-performance polymers, bioresorbables, and additively manufactured implants, and the presence of major players including Zimmer Biomet, Stryker, Medtronic, and Johnson & Johnson. Disease burden is substantial, with a large aging population and high prevalence of cardiovascular and musculoskeletal disease. The regulatory environment is well established, with the Food and Drug Administration providing clearance and approval pathways for implantable materials and devices. Strong research infrastructure, biomaterials innovation, and investment further reinforce the market. This combination of procedure volume, technology adoption, and manufacturer presence reinforces North America's leadership in the global market.

Fastest Growing Region: Asia-Pacific

Asia-Pacific is the fastest-growing region in the Biomaterials market. The region's elevated CAGR is driven by large populations, a rising burden of chronic and age-related disease, expanding healthcare access, and growing volumes of orthopedic, cardiovascular, and dental procedures across China, India, Japan, South Korea, and Southeast Asia. Rising incomes, expanding insurance coverage, and growing investment in healthcare and surgical capacity are increasing access to implants and biomaterial-based devices, and aging populations in several countries expand demand. China and India are expanding domestic medical device and materials manufacturing, broadening access and lowering costs, and rising awareness and diagnosis increase procedure volumes. Both multinational and regional manufacturers are expanding their presence. Government investment in healthcare infrastructure further supports growth. The combination of large populations, rising disease burden, expanding access, and growing procedure volumes positions Asia-Pacific as the highest-growth region over the forecast period.

Biomaterials Market Regional Commentary

North America

North America accounted for 35% of the global Biomaterials market revenue in 2025. The United States dominates the region on the strength of advanced healthcare infrastructure, high procedure volumes, rapid adoption of advanced biomaterials, and the presence of leading device and material manufacturers, while Canada contributes through its healthcare system and Mexico expands access within its growing healthcare and medical device sector.

Europe

Europe represents the second-largest regional market, led by Germany, France, and the United Kingdom. Growth is supported by a high burden of age-related disease, established device and materials industries, and the presence of major manufacturers such as Evonik, BASF, and Straumann, while the European Medical Device Regulation shapes product requirements and market access across the region.

Asia-Pacific

Asia-Pacific is the fastest-growing region, propelled by large populations, a rising burden of chronic and age-related disease, expanding healthcare access, and growing procedure volumes across China, India, Japan, South Korea, and Southeast Asia. Expanding domestic device and materials manufacturing is broadening access and adoption.

Rest of World

The Rest of World region, spanning the Middle East, Africa, and South America, is an emerging growth frontier. A rising burden of chronic disease, improving healthcare and surgical infrastructure, and expanding access to implants and devices are broadening adoption, while investment in healthcare supports growth.

Biomaterials Market Competitive Landscape

The Biomaterials market is classified as Fragmented. A broad field of medical device companies and specialty material manufacturers competes across material types and applications, led by device leaders such as Zimmer Biomet, Stryker, Medtronic, and Johnson & Johnson, and specialty material suppliers such as Evonik, BASF, Corbion, and Victrex, while dental and natural biomaterial specialists such as Straumann and Collagen Matrix and numerous regional players compete across the market.

The competitive landscape can be evaluated across the following dimensions:

  • Market concentration: Fragmented, spanning large medical device companies, specialty material manufacturers, and numerous regional and application-specific players.
  • Leading players: Zimmer Biomet, Stryker, Medtronic, and Johnson & Johnson lead in biomaterial-based devices, while Evonik, BASF, Corbion, and Victrex lead in specialty materials and Straumann and Collagen Matrix in dental and natural biomaterials.
  • Geographic reach: Leaders operate global commercial, manufacturing, and research networks, with strong positions across North America, Europe, and Asia-Pacific.
  • Product portfolio strength: Players hold portfolios spanning metallic, polymeric, ceramic, and natural biomaterials and biomaterial-based devices across applications.
  • Pipeline strength: Deep pipelines in bioresorbable and high-performance polymers, bioactive ceramics, additively manufactured implants, and natural and regenerative biomaterials.
  • Strategic partnerships: Extensive collaboration between material suppliers and device manufacturers shapes the development and supply of biomaterials.
  • M&A activity: Consolidation and acquisitions continue across device and materials companies to expand biomaterial capabilities.
  • Manufacturing capabilities: Specialized material production, medical-grade manufacturing, and additive manufacturing are key competitive strengths and barriers to entry.
  • Innovation focus: Bioresorbable and bioactive materials, high-performance polymers, additive manufacturing, surface engineering, and regenerative and natural biomaterials.

Biomaterials Market Recent Developmental Activities

  • In 2023 and 2024, Evonik expanded its RESOMER bioresorbable polymer and biomaterials portfolio for medical devices, including materials for controlled-resorption implants and drug delivery. Strategic significance: Strengthens leadership in bioresorbable biomaterials and supports device innovation.
  • In 2023 and 2024, Victrex and Invibio expanded their PEEK-OPTIMA high-performance polymer portfolio for spinal, trauma, and other implants, including additive manufacturing applications. Strategic significance: Advances high-performance polymer alternatives to metal and expands applications.
  • In 2023 and 2024, additive manufacturing, or three-dimensional printing, of titanium, polymer, and ceramic implants expanded across orthopedic and dental applications, enabling patient-specific and porous designs. Strategic significance: Expands the use of advanced manufacturing to improve implant integration and outcomes.
  • In 2023 and 2024, device leaders including Zimmer Biomet, Stryker, Medtronic, and Johnson & Johnson advanced biomaterial-based implant portfolios across orthopedics and cardiovascular medicine. Strategic significance: Sustains demand for metallic, polymeric, and ceramic biomaterials in high-value implants.
  • In 2024, Humacyte received FDA approval for its bioengineered acellular vessel, Symvess, for vascular trauma, advancing engineered tissue-based biomaterials. Strategic significance: Marks progress for engineered and regenerative biomaterials in clinical use.
  • In 2023 and 2024, natural biomaterials including collagen and hyaluronic acid expanded in wound healing, dental, and regenerative applications. Strategic significance: Strengthens the natural biomaterials segment and regenerative medicine applications.
  • In 2023 and 2024, bioactive ceramics and bone graft substitutes, including hydroxyapatite and calcium phosphate materials, expanded in orthopedic and dental bone repair. Strategic significance: Advances ceramic biomaterials for bone regeneration.
  • In 2023 and 2024, specialty material manufacturers and device companies expanded collaborations to develop and supply advanced biomaterials tailored to device applications. Strategic significance: Accelerates the translation of new materials into medical devices.
  • In 2023 and 2024, surface engineering and bioactive coatings advanced to improve osseointegration, antimicrobial performance, and biocompatibility of implants. Strategic significance: Improves implant performance and expands material capabilities.
  • In 2023 and 2024, the European Medical Device Regulation continued to reshape requirements and market access for implantable materials and devices in Europe. Strategic significance: Raises compliance requirements and influences portfolio and market-entry strategies.
  • In 2023 and 2024, investment and research in regenerative medicine, tissue engineering, and bioprinting expanded, increasing demand for advanced and natural biomaterials. Strategic significance: Expands the pipeline of biomaterial applications in regenerative medicine.
  • In 2023 and 2024, regional manufacturers in Asia expanded biomaterial and implant production, broadening access and intensifying competition. Strategic significance: Expands access in high-growth emerging markets and increases competition.

Biomaterials Market Segmentation

  • Biomaterials Market by Type of Material
    • Metallic Biomaterials
    • Polymeric Biomaterials
    • Ceramic Biomaterials
    • Natural Biomaterials
  • Biomaterials Market by Application
    • Cardiovascular
    • Orthopedic
    • Dental
    • Ophthalmology
    • Wound Healing
    • Tissue Engineering
    • Plastic Surgery
    • Neurology
    • Others
  • Biomaterials Market by End-User
    • Hospitals and Clinics
    • Ambulatory Surgical Centers
    • Academic and Research Institutes
    • Others

Biomaterials Market Assessment by Geography

  • North America Biomaterials Market Assessment
    • United States Biomaterials Market Size in USD million (2023-2034)
    • Canada Biomaterials Market Size in USD million (2023-2034)
    • Mexico Biomaterials Market Size in USD million (2023-2034)
  • Europe Biomaterials Market Assessment
    • Germany Biomaterials Market Size in USD million (2023-2034)
    • United Kingdom Biomaterials Market Size in USD million (2023-2034)
    • France Biomaterials Market Size in USD million (2023-2034)
    • Italy Biomaterials Market Size in USD million (2023-2034)
    • Spain Biomaterials Market Size in USD million (2023-2034)
    • Rest of Europe Biomaterials Market Size in USD million (2023-2034)
  • Asia-Pacific Biomaterials Market Assessment
    • China Biomaterials Market Size in USD million (2023-2034)
    • Japan Biomaterials Market Size in USD million (2023-2034)
    • India Biomaterials Market Size in USD million (2023-2034)
    • Australia Biomaterials Market Size in USD million (2023-2034)
    • South Korea Biomaterials Market Size in USD million (2023-2034)
    • Rest of Asia-Pacific Biomaterials Market Size in USD million (2023-2034)
  • Rest of the World (RoW) Biomaterials Market Assessment
    • Middle East Biomaterials Market Size in USD million (2023-2034)
    • Africa Biomaterials Market Size in USD million (2023-2034)
    • South America Biomaterials Market Size in USD million (2023-2034)

Biomaterials Market Recent Industry Trends and Milestones (2023-2026):

Category

Key Developments

Biomaterials Market Product Approval

Humacyte received FDA approval for its bioengineered vessel Symvess (2024); manufacturers secured clearances and approvals for biomaterial-based implants and additively manufactured devices; the European Medical Device Regulation continued to shape requirements for implantable materials.

Biomaterials Market Product Expansion

Evonik expanded RESOMER bioresorbable biomaterials; Victrex and Invibio expanded PEEK-OPTIMA polymers; device leaders expanded biomaterial-based implant portfolios; additive manufacturing of titanium, polymer, and ceramic implants expanded; natural and bioactive ceramic biomaterials expanded.

Biomaterials Market Product Investment

Specialty material and device companies invested in bioresorbable and high-performance polymers, bioactive ceramics, additive manufacturing, and regenerative biomaterials; collaborations between material suppliers and device manufacturers expanded; regional manufacturers invested in biomaterial and implant production.

Biomaterials Market Company Strategy

Zimmer Biomet, Stryker, Medtronic, and Johnson & Johnson: Biomaterial-based implants across orthopedics and cardiovascular medicine. Evonik Industries AG, BASF SE, Corbion N.V., and Victrex plc: Specialty bioresorbable, high-performance, and medical polymers. Institut Straumann AG and Collagen Matrix, Inc.: Dental and natural biomaterials.

Biomaterials Market Emerging Technologies

Bioresorbable and bioactive polymers and ceramics; high-performance polymers such as PEEK; additive manufacturing of patient-specific and porous implants; surface engineering and antimicrobial and osseointegrative coatings; natural biomaterials and scaffolds; and bioprinting and regenerative medicine materials.

Biomaterials Market Startup Funding and Investment Trends

Investment in the biomaterials ecosystem has concentrated on regenerative and engineered biomaterials, bioprinting, and advanced bioresorbable and tissue-repair materials. The following companies illustrate recent activity and technology focus.

Company

Total Funding

Funding Stage

Main Product

Core Technology

CollPlant Biotechnologies Ltd.

Public and venture funding

Public / growth-stage

Plant-based recombinant collagen and bioprinting

Plant-derived recombinant human collagen for regenerative and bioprinted products

Tissium SA

Venture funding

Growth-stage venture

Programmable biomorphic polymer platform

Biomorphic, bioresorbable, light-activated polymers for tissue repair

 

Request for unlocking the report of the @ Biomaterials Market Insights

 

CollPlant Biotechnologies is developing plant-derived recombinant human collagen for regenerative medicine, tissue repair, and bioprinting applications, while Tissium develops programmable, bioresorbable biomorphic polymers for tissue reconstruction and repair. Additional capital continues to flow toward regenerative and engineered biomaterials, bioprinting, bioresorbable materials, and advanced tissue-repair technologies, reflecting conviction that materials that integrate with, support, or regenerate tissue are the next source of competitive advantage. Collectively, these efforts signal sustained investment in expanding the performance and applications of biomaterials and in addressing unmet needs in tissue repair and regenerative medicine.

Key Takeaways from the Biomaterials Market Report Study

  • Market size analysis for the current biomaterials market size (2025), and market forecast for 9 years (2026 to 2034).
  • Top key product/technology developments, mergers, acquisitions, partnerships, and joint ventures that happened over the last 3 years.
  • Key companies dominating the global biomaterials market.
  • Various opportunities available for competitors in the biomaterials market space.
  • What are the top-performing segments in 2025? How will these segments perform in 2034?
  • Which are the top-performing regions and countries in the current biomaterials market scenario?
  • Which are the regions and countries where companies should concentrate their opportunities for biomaterials market growth in the future?

Target audience who can benefit from this biomaterials market report study

  • Biomaterials product providers
  • Research organizations and consulting companies
  • Biomaterials-related organizations, associations, forums, and other alliances
  • Government and corporate offices
  • Start-up companies, venture capitalists, and private equity firms
  • Distributors and traders dealing in biomaterials
  • Various end-users who want to know more about the biomaterials market and the latest technological developments in the biomaterials market.

Frequently Asked Questions

Q1. What is the growth rate of the Biomaterials market?

The Biomaterials market is projected to expand at a CAGR of 13.5% during the forecast period of 2026-2034.

Q2. What is the market size of the Biomaterials market?

The Biomaterials market size is estimated at USD 52 billion in 2025 and is projected to reach USD 162 billion by 2034.

Q3. Which region dominates the Biomaterials market?

North America dominated the Biomaterials market with a 35% share of global revenue in 2025, supported by advanced healthcare infrastructure, high procedure volumes, rapid adoption of advanced biomaterials, supportive FDA pathways, and the presence of leading device and material manufacturers. Asia-Pacific is the fastest-growing region over the forecast period.

Q4. What are the key drivers of the Biomaterials market?

The principal drivers are rising demand for implantable medical devices; the aging population and rising burden of chronic disease; the growth of regenerative medicine and tissue engineering; and technological advancement in bioresorbable and high-performance materials and additive manufacturing, reinforced by the rising volume of orthopedic, cardiovascular, and dental procedures and growing research investment and industry collaboration.

Q5. Who are the major players in the Biomaterials market?

The major Biomaterials companies in the market include - include Zimmer Biomet Holdings, Inc., Stryker Corporation, Medtronic plc, Johnson & Johnson, Evonik Industries AG, BASF SE, Corbion N.V., Victrex plc, Institut Straumann AG, and Collagen Matrix, Inc., among other active manufacturers profiled in the Competitive Landscape section. Device leaders dominate biomaterial-based implants, while Evonik, Victrex, and other specialty suppliers lead in advanced materials such as bioresorbable and high-performance polymers.

Tags:

  • Biomaterials
  • Biomaterials Mechanism
  • Biomaterials Companies
  • Biomaterials Medical devices

License Type


Offer

Request Sample

View Pricing

Customize Reports As Per Your Needs

Don't see what you're looking for? Get a report tailored to your specific requirements. Customize your report now!

Have a Question?

We are happy to assist you.

DelveInsight
DelveInsight
SUBSCRIPTION
Platform

Register for free trial today and gain instant access to 7000+ market
research reports